Investor Presentaiton

Investor Presentation First six months of 2018 SUSTAIN phase 3a trials with semaglutide successfully completed SUSTAIN Baseline UT 1 2 3 4 5 8.1% 8.1% 8.3% 8.2% 0.0 -0.5 8.4% -0.1 6 8.7% Change in HbA1c (%) -1.3 -1.5 -1.6 -1.6 -1.5 * -0.9 -0.8 -1.2 -1.6 * -0.4 -1.1 -1.4 -1.4 -1.8 Baseline 92 kg 89 kg 96 kg 93 kg 1.2 92 kg 92 kg -1.0 -1.4 -0.6 -1.9 -1.9 Change in weight (kg) -3.7 -4.5 -3.5 -4.3 -5.2 -5.6 -6.1 -3.7 -3.6 -4.9 * -6.4 semaglutide 1 mg semaglutide 0.5 mg Placebo¹ sitagliptin 100 mg exenatide ER glargine U100 * Statistically significant; 1 SUSTAIN 1: Once-weekly semaglutide versus placebo in drug-naïve subjects with type 2 diabetes; SUSTAIN 5: Once-weekly semaglutide versus placebo in subjects with type. 2 diabetes added to insulin; SUSTAIN 6: Once-weekly semaglutide versus placebo, added to standard-of-care ER: Extended-release Slide 74 novo nordisk

View entire presentation